Current Report Filing (8-k)
January 10 2022 - 7:17AM
Edgar (US Regulatory)
0001745020false00017450202022-01-102022-01-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date Earliest Event Reported):
January 10, 2022
Theseus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-40869
|
|
83-0712806
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
245 Main Street
Cambridge, Massachusetts
(Address of Principal Executive Offices)
|
|
02142
(Zip Code)
|
(857) 400-9491
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on
which registered
|
Common stock, par value $0.0001 per share
|
|
THRX
|
|
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On January 10, 2022, Theseus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the first patient has been treated in the Phase 1 portion of the Company’s ongoing Phase 1/2 study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors, as well as indicating its expectations with respect to the presentation of initial data from the Phase 1 portion of the clinical trial. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Theseus Pharmaceuticals, Inc.
|
|
|
|
By:
|
/s/ Bradford D. Dahms
|
|
|
Name: Bradford D. Dahms
|
|
|
Title: Chief Financial Officer
|
Date: January 10, 2022
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Apr 2023 to Apr 2024